The earnings call reflects a positive sentiment with significant achievements in commercial sales and clinical trial progress, despite challenges in sales infrastructure and ongoing R&D expenses.

Company Guidance

During the RenovoRx second quarter 2025 conference call, the company provided several key metrics and updates. The RenovoCath device achieved over $400,000 in sales during the second quarter, marking significant early progress without a dedicated sales and marketing team. Ninety-five patients have been randomized in the Phase III TIGR PACT trial, with sixty-one events recorded, aiming to complete enrollment by late 2025 or early 2026. The company reported a revenue of approximately $422,000 for the quarter ending June 30, 2025, with research and development expenses at $1.4 million, reflecting a $100,000 decrease year-over-year. The company ended the quarter with $12.3 million in cash and cash equivalents. Looking ahead, RenovoRx estimates a total addressable market for RenovoCath as a standalone device of $400 million annually in the U.S., with potential expansion into a multi-billion dollar market as they explore additional cancer indications. The company's commercial strategy and clinical progress, including the positive recommendation from the DMC to continue the TIGR PACT trial, highlight a promising trajectory for RenovoRx in the oncology field.

Commercialization Success

RenovoRx achieved over $400,000 in sales in Q2 2025 without a dedicated sales and marketing team, highlighting strong market demand for the RenovoCath device.

Positive Interim Analysis for TIGR PACT Trial

The independent Data Monitoring Committee (DMC) recommended the continuation of the Phase III TIGR PACT trial, indicating confidence in a potential positive outcome.

Strong Financial Position

RenovoRx ended the quarter with $12.3 million in cash and cash equivalents, sufficient to fund ongoing commercial and clinical activities.

Panther Registry Study Launch

RenovoRx launched the Panther study to evaluate the real-world safety and effectiveness of RenovoCath in solid tumors, marking a significant step in understanding the device's long-term potential.

Market Expansion Potential

RenovoRx estimates a $400 million peak annual U.S. sales opportunity for RenovoCath as a standalone device, with potential expansion into a several billion dollar market for additional cancer applications.

RenovoRx (RNXT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

RNXT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 17, 2025	2025 (Q3)	-0.08 / -	-0.1	―	―	―
Aug 14, 2025	2025 (Q2)	-0.09 / -0.08	-0.1	20.00% (+0.02)	―
May 15, 2025	2025 (Q1)	- / -0.08	-0.07	-14.29% (>-0.01)	―
Apr 01, 2025	2024 (Q4)	-0.08 / -0.08	-0.07	-14.29% (>-0.01)	―	―
Nov 14, 2024	2024 (Q3)	-0.12 / -0.10	-0.13	23.08% (+0.03)	―	―
Aug 14, 2024	2024 (Q2)	-0.10 / -0.10	-0.22	54.55% (+0.12)	―	―
May 13, 2024	2024 (Q1)	-0.13 / -0.07	-0.36	80.56% (+0.29)	―	―
Mar 27, 2024	2023 (Q4)	-0.30 / -0.30	-0.24	-27.08% (-0.07)	―	―
Nov 14, 2023	2023 (Q3)	-0.28 / -0.13	-0.24	45.83% (+0.11)	―	―
Aug 17, 2023	2023 (Q2)	-0.29 / -0.22	-0.29	24.14% (+0.07)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

RNXT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 14, 2025	$1.24	$0.96	-22.58%
May 15, 2025	$1.11	$1.18	+6.31%
Apr 01, 2025	$0.99	$0.96	-3.03%
Nov 14, 2024	$1.09	$1.09	0.00%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does RenovoRx (RNXT) report earnings?

RenovoRx (RNXT) is schdueled to report earning on Nov 17, 2025, After Close (Confirmed).

What is RenovoRx (RNXT) earnings time?

RenovoRx (RNXT) earnings time is at Nov 17, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is RNXT EPS forecast?

RNXT EPS forecast for the fiscal quarter 2025 (Q3) is -0.08.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing